BioPharmSignal logoBioPharmSignal

Biotech News

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Inflarx NV (IFRX)Inflarx NVEarnings

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced financial results for the three months ended June 30, 2026, and provided a business update.

Related news

IFRXInflarx NV2026-07-30 11:30 EST

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

INMBINmune Bio2026-08-06 20:00 EST

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

ALECAlector2026-08-06 20:05 EST

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

CLDXCelldex Therapeutics2026-08-06 20:01 EST

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

ACRSAclaris Therapeutics2026-08-06 10:59 EST

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

View all latest news

Inflarx NV

Complement-Targeted Immunology InflaRx develops anti-inflammatory therapies that inhibit the complement C5a pathway. Its portfolio includes an oral C5a receptor inhibitor and an antibody against C5a. Izicopan Izicopan is an oral C5aR inhibitor designed for differentiated chemistry, metabolic properties and safety. Phase 2a results in...

Recent company news

IFRXInflarx NV2026-08-06 11:30 EST

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

IFRXInflarx NV2026-07-30 11:30 EST

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

IFRXInflarx NV2026-06-30 11:30 EST

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

IFRXInflarx NV2026-05-08 12:15 EST

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

IFRXInflarx NV2026-05-06 12:30 EST

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

Stock data

Close
1.72 USD
Market cap
319.63M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States